October 15, 2018 5:00 PM
Hauser Hall, Room 104
Harvard Law School, 1575 Massachusetts Ave., Cambridge, MA
Download the Presentation: “Health Impact Assessment: A Negative Right to Health”
Professor Christina S. Ho is Professor of Law at Rutgers Law School. She joined the Rutgers faculty in 2010 from the O’Neill Institute for National and Global Health Law at Georgetown University Law Center, where she was a Senior Fellow and Project Director of the China Health Law Initiative. She was previously Country Director and senior policy advisor for the Clinton Foundation’s China program. During the Clinton Administration, she worked on the Domestic Policy Council at the White House and later led Senator Hillary Rodham Clinton’s health legislative staff.
Professor Ho received her AB from Harvard College, her MPP from Harvard’s John F. Kennedy School of Government, and her JD from Harvard Law School.
This year, several states applied for and received permission from the federal government to implement work requirements in their Medicaid programs. Policy designs vary by state, but all states build in considerations for people with disabilities. These considerations include exemptions and exceptions from work requirements for individuals unable to work due to a disability.
But how can states implement these policies in a way that is accurate, efficient, and fair?
By John Tingle
Good communication is an essential prerequisite for good and safe patient care. To effectively communicate is an everyday life skill and it’s one of the most basic that we all must master in some way. From a patient safety context poor health carer communication practices are a worldwide problem which continues to cause global patient harm.The WHO state that communication failures are the leading cause of inadvertent patient harm.Successive Health Service Ombudsman in England have maintained that communication failures are a leading cause of patient complaints. In 2014-2015 poor communication, including quality and accuracy of information, was a factor in one third of all health care complaints.
By Rebecca Friedman
Short-term, limited-duration insurance was designed as a temporary gap-filler while a person transitions from one kind of health insurance to a different plan or coverage. In 2016, recognizing its serious limitations, an Obama Administration rule mandated that coverage of short-term, limited-duration insurance be limited to three months, including any period of renewal.
But due to a final rule in August 2018 from the Trump Administration, short-term, limited-duration insurance coverage contracts can now last as long as one day short of a year, and can last as long as three years with renewals or extensions. The Trump Administration explained in its final rule that it selected this standard to promote access to choices of health coverage and to individual health insurance coverage. The rule also acknowledged this kind of insurance may not be the most appropriate or affordable for everyone. As of Tuesday, October 2, insurers can sell these “skimpy” plans for the extended duration.
By Mark Robinson and Joseph M. Gabriel
In a previous post, one of us has argued that bioethical deliberation needs to incorporate an analysis of “market forces in health-related decision-making” under what might be called “economic bioethics.”
To a certain extent, of course, bioethicists already do this. Industry-physician relations, for example, attracts substantial attention from the field. Other notable topics include the price of health-care services and technologies (and drugs in particular), patenting biological material, debates about funding controversial types of medical research, and debates about the allocation of resources during times of scarcity.
By Rahul Nayak
With the 2018 midterm elections fast approaching, there are key some voter propositions with important health implications.
Most notably, this November, voters in three conservative states — Idaho (Proposition 2), Utah (Proposition 3), and Nebraska (Initiative 427) — will be deciding on whether to expand Medicaid. In addition, voters in Montana will decide whether to permanently extend their state’s Medicaid expansion. This is coming at the heels of the closely watched November 2017 referendum where Mainers decisively supported Medicaid expansion 59 percent to 41 percent.
By Leslie Francis
As a scholar working in health law and bioethics, a persistent concern of mine has been the somewhat limited connections between those fields and scholars in the social sciences, particularly political science, economics, and sociology.
Perhaps the best venue for interchange among the social sciences and law may be less well known among folks in health law and bioethics than it should be (at least to judge from inquiries I received when I posted a recent call for papers on the mcw bioethics listserv): the Law and Society Association (LSA).
By Leslie C. Griffin
The New Yorker just published an article full of ethical questions about the best health care treatment for dementia patients. It should make you think about which life you would choose. Larissa MacFarquhar’s piece is titled “The Comforting Fictions of Dementia Care.” Its subtitle suggests a sad story, noting “Many facilities are using nostalgic environments as a means of soothing the misery, panic, and rage their residents experience.” The article tells numerous powerful stories of dementia patients’ good and bad experiences.
By Nicolas Terry
We are delighted to announce this year’s Hall Center for Law and Health: Indiana Health Law Review Symposium, The Intersection of Immigration Law and Health Policy, Friday, October 26, 2018, Indiana University Robert H. McKinney School of Law. Registration link. Our speakers include, in order of appearance:
- Wendy E. Parmet, JD, Matthews Distinguished University Professor of Law and Director, Center for Health Policy and Law; Professor of Public Policy and Urban Affairs, Northeastern University School of Public Policy and Urban Affairs
- Melissa D. Anderson, MD, Assistant Professor of Clinical Medicine – Nephrology, Indiana University School of Medicine
- Brietta R. Clark, JD, Professor of Law and J. Rex Dibble Fellow, Loyola Law School Los Angeles
- Y.Y. Brandon Chen, JD, MSW, Assistant Professor Faculty of Law, University of Ottawa
- Grace E. Shelton, JD, Attorney, Hall Render Killian Heath & Lyman, P.C.
- Maurice Henein, MD FAAFP, Program Director, Community East Family Medicine Residency, Indianapolis
- Lori A. Nessel, JD, Professor of Law, Center for Social Justice Director, Seton Hall University School of Law
- Emma Mahern, JD, Associate Attorney, Muñoz Legal
- Sister Tracy Horan, Sisters of Providence of Saint Mary of the Woods, Bilingual Community Organizer Archdiocese of Indianapolis Justice for Immigrants Campaign
- Medha D. Makhlouf, JD, Assistant Professor of Law, Director, Medical-Legal Partnership Clinic, Penn State’s Dickinson School of Law
- Valarie K. Blake, JD, MA, Associate Professor, West Virginia College of Law
- Jonathan Todres, JD, Professor of Law, Center for Law Health and Society, Georgia State University College of Law
- Ellen Einterz, MD, Marion County Public Health Department
- Polly J. Price, JD, Asa Griggs Candler Professor of Law, Emory University School of Law
- Cecilia S. Obeng, PhD, Associate Professor of Applied Health Science, Indiana University Bloomington School of Public Health
By Ameet Sarpatwari, Michael S. Sinha, and Aaron S. Kesselheim
Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues relevant to current or potential future work in the Division.
Below are the abstracts/summaries for papers identified from the month of September. The selections feature topics ranging from the impact of the FDA Amendments Act of 2007; to the estimated cost of pivotal trials for FDA-approved novel therapeutic agents, to labeling changes and costs for clinical trials performed under the FDA pediatric exclusivity extension. A full posting of abstracts/summaries of these articles may be found on our website.
- Avorn J, Kesselheim A, Sarpatwari A. The FDA Amendments Act of 2007 – Assessing Its Effects a Decade Later. N Engl J Med. 2018 Sep 20;379(12):1097-1099.
- Hernandez I, Sampathkumar S, Good CB, Kesselheim AS, Shrank WH. Changes in Drug Pricing After Drug Shortages in the United States. Ann Intern Med. 2018 Sep 18. [Epub ahead of print]
- Moore TJ, Zhang H, Anderson G, Alexaner GC. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration. JAMA Intern Med. 2018 Sep 24. [Epub ahead of print]
- Nishikawa G, Prasad V. Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. BMJ. 2018 Sep 19;362:k3783.
- Sinha MS, Najafzadeh M, Rajasingh EK, Love J, Kesselheim AS. Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012. JAMA Intern Med. 2018 Sep 24. [Epub ahead of print]
By James Toomey
Professor S. Matthew Liao of NYU presented a paper last week at the Health Law, Bioethics, and Biotechnology Workshop. Liao’s theory of rights-worthiness is based on the presence of a genetic basis for a moral sense. So babies, fetuses, the vetegative, all are human rights-holders, other animals are presumptively not (but could be if we found they had the genes for moral sense) and, with a little line drawing about the nature of an organism, corpses are excluded.
It is, perhaps, a somewhat strained effort to justify a deep moral intuition that all human beings, no matter how brain-damaged, are entitled on their own merit to a full panoply of human rights.
Personally, I’m skeptical. Continue reading
By Mark Satta
The slogan “healthcare for all” typically stands as a proxy claim for “health insurance for all.” Given the Trump Administration’s recurrent attempts to decrease the effectiveness of President Obama’s comprehensive health insurance regulation reform law, the Affordable Care Act, it’s understandable that health insurance would be a major focus of those concerned with reforming the health care system. Millions of Americans remain uninsured and/or unable to pay for the health services they need, so continued efforts to reform our health insurance system remain vital.
Photo by picstever/Flickr
By Alexandra Slessarev
Among the coverage of the aftermath of Hurricane Florence, news stories about the overflowing waste from North Carolina pig lagoons were among the most stomach-turning. North Carolina is home to a slew of concentrated animal feeding operations, or CAFOs, and these industrial livestock farming operations often involve storing massive volumes of pig manure in contained “lagoons.”
The driving rain from Hurricane Florence caused at least 110 of these lagoons to swell over. CAFOs are, in themselves, a topic of concern among public health and environmental justice advocates. But this specific example of what happens when CAFOs and extreme weather patterns collide provides an opportunity to reflect on the unique relationship between public health and climate change.
Please join us for a conversation with John Carreyrou, Investigative reporter for the Wall Street Journal and author of the New York Times bestseller “Bad Blood: Secrets and Lies in a Silicon Valley Startup.”
Carreyrou will discuss his book about the rise and fall of Silicon Valley darling, the blood testing company Theranos, and its charismatic, Stanford drop-out CEO, Elizabeth Holmes.
In recent weeks, news has emerged that the company will in fact cease operations, despite a short-lived attempt to survive after removing Holmes.
By Hugo Caicedo
Traditional medical practice is rooted in advanced knowledge of diseases, their most appropriate treatment, and adequate proficiency in its applied practice. Notably, today, medical treatment does not typically occur until disease symptoms have manifested. While we now have ways to develop therapies that can halt the progression of some symptomatic diseases, symptomatic solutions are not meant to serve as a cure of disease but palliative treatment of late-stage chronic diseases.
The reactive approach in most medical interventions is magnified in that medicine is prone to errors. In November of 1999, the U.S. National Academy of Science, an organization representing the most highly regarded scientists and physician researchers in the U.S., published the report To Err is Human.
October 1, 2018 5:00 PM
Hauser Hall, Room 104
Harvard Law School, 1575 Massachusetts Ave., Cambridge, MA
Presentation: “The Moral Status and Rights of Artificial Intelligence”
To request a copy of the paper in preparation for the workshop, please contact Jennifer Minnich at jminnich at law.harvard.edu.
S. Matthew Liao is Director of Center for Bioethics and Arthur Zitrin Professor of Bioethics at the NYU College of Global Public Health. He uses the tools of philosophy to study and examine the ramifications of novel biomedical innovations.